Key Highlights
- PharmaJet announces Wouter Latour, M.D., as new CEO.
- Latour brings over 30 years of industry experience, including leadership at Vaxart, Inc.
- Chris Cappello appointed Vice-Chairman and remains active in strategic partnerships.
- PharmaJet’s needle-free delivery technology advances vaccine and therapeutic effectiveness.
Source: Business Wire
Notable Quotes
- “I am pleased to welcome Dr. Latour to PharmaJet and want to express my sincere confidence in him as he assumes the leadership of the Company.” — Gordon Clancy, Chairman of the Board at PharmaJet
- “This is an exciting time for PharmaJet with tremendous prospects for growth and value creation.” — Wouter Latour, CEO at PharmaJet
SoHC's Take
Wouter Latour’s appointment as CEO marks a strategic leadership move for PharmaJet as it aims to expand its needle-free delivery systems for vaccines and therapeutics. His extensive biotech background, particularly with vaccine innovation at Vaxart, positions PharmaJet for strong execution in emerging vaccine markets. The company’s technology, already instrumental in global polio campaigns, now stands poised for broader application in immunotherapies, exemplified by the recent collaboration with Scancell on a DNA melanoma vaccine. With this leadership shift, PharmaJet is well-equipped to further redefine the field of vaccine delivery.
